Epigenomics' FY 2010 Revenues Fall 58 Percent | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Epigenomics today reported that its full-year 2010 revenues declined 58 percent, due to non-recurring revenue in 2009 tied to R&D support for partners.

The Berlin, Germany-based firm said that its 2010 revenues were €1.8 million ($2.6 million), down from €4.3 million in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.